High dose aerosol pentamidine for secondary Pneumocystis carinii pneumonia prophylaxis in AIDS patients
Related Experiment Videos
L Flamholc1, S Haidl, E Westin
1Dept. of Infectious Diseases, Malmö General Hospital, University of Lund, Sweden.
Infection
|November 1, 1992
Insights
Aerosolized pentamidine effectively prevented Pneumocystis pneumonia (PCP) relapses in 18 patients. This secondary prophylaxis showed no serious side effects during the trial.
Area of Science:
- Pulmonology
- Infectious Diseases
- Pharmacology
Background:
- Pneumocystis pneumonia (PCP) is a serious opportunistic infection.
- Secondary prophylaxis is crucial for patients with a history of PCP.
- Aerosolized pentamidine has been used for PCP treatment and prophylaxis.
Purpose of the Study:
- To evaluate the efficacy and safety of aerosolized pentamidine for secondary PCP prophylaxis.
- To determine the optimal dosage and administration method for aerosolized pentamidine in this context.
Main Methods:
- A prospective trial involving 18 patients receiving aerosolized pentamidine.
- Dosage: 400 mg administered once weekly.
- Administration: MA2 jet nebulizer.
- Duration: Mean follow-up of 15.5 months.
Main Results:
- No cases of PCP relapse were observed in the study group.
- No serious adverse events were reported during the treatment period.
- The MA2 jet nebulizer facilitated effective aerosol delivery.
Conclusions:
- Aerosolized pentamidine is a safe and effective option for secondary PCP prophylaxis.
- Weekly administration of 400 mg pentamidine is well-tolerated.
- Further research may explore long-term outcomes and alternative delivery methods.
Abstract:
In a prospective trial of aerosolized pentamidine as secondary prophylaxis for Pneumocystis carinii pneumonia (PCP) 18 patients received 400 mg once weekly for a mean period of 15.5 months. Pentamidine aerosol was administered with an MA2 jet nebulizer. No PCP relapses were observed and no serious side effects occurred.